This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Jun 7;8(7):384.

doi: 10.1038/nrclinonc.2011.86.

Targeted therapies: Radiopeptide therapy improves outcomes for neuroendocrine cancers

Lisa Hutchinson

PMID: 21647196
DOI: 10.1038/nrclinonc.2011.86

Comment

Targeted therapies: Radiopeptide therapy improves outcomes for neuroendocrine cancers

Lisa Hutchinson. Nat Rev Clin Oncol. 2011.

. 2011 Jun 7;8(7):384.

doi: 10.1038/nrclinonc.2011.86.

Author

Lisa Hutchinson

PMID: 21647196
DOI: 10.1038/nrclinonc.2011.86

No abstract available

PubMed Disclaimer

Comment on

Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.
Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, Mäcke HR, Rochlitz C, Müller-Brand J, Walter MA. Imhof A, et al. J Clin Oncol. 2011 Jun 10;29(17):2416-23. doi: 10.1200/JCO.2010.33.7873. Epub 2011 May 9. J Clin Oncol. 2011. PMID: 21555692 Clinical Trial.

References

1. J Clin Oncol. 2011 Jun 10;29(17):2416-23 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.